Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways

Experimental Cell Research

Volumn 331, Issue 1, 2015, Pages 152-163

  Gilet, Alexandre ^a   Zou, Feng ^a,b   Boumenir, Meriem ^a   Frippiat, Jean Pol ^c   Thornton, Simon N ^a   Lacolley, Patrick ^a   Ropars, Armelle ^a,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b JIANGHAN UNIVERSITY   (China)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Aldosterone; Inflammation; MAP kinases; MMP 9; Neutrophil; NGAL

Indexed keywords

ALDOSTERONE; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHATIDYLINOSITOL 3 KINASE; SPIRONOLACTONE; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; MMP9 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REPAIR; UPREGULATION; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENETICS; HL 60 CELL LINE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACUTE-PHASE PROTEINS; ALDOSTERONE; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; HL-60 CELLS; HUMANS; LIPOCALINS; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84921033706     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.11.004     Document Type: Article

References (53)

1. Rocha R., Chander P.N., Zuckerman A., Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232-237.
2. Sun Y., Ramires F.J., Weber K.T. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc. Res. 1997, 35:138-147.
3. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
4. Schjoedt K.J., Rossing K., Juhl T.R., Boomsma F., Tarnow L., Rossing P., Parving H.H. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006, 70:536-542.
5. Yamanaka R., Otsuka F., Nakamura K., Yamashita M., Otani H., Takeda M., Matsumoto Y., Kusano K.F., Ito H., Makino H. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. Hypertens. Res. 2010, 33:435-445.
6. Maron B.A., Zhang Y.Y., Handy D.E., Beuve A., Tang S.S., Loscalzo J., Leopold J.A. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J. Biol. Chem. 2009, 284:7665-7672.
7. Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. 2002, 103:425-431.
8. Hillebrand U., Schillers H., Riethmüller C., Stock C., Wilhelmi M., Oberleithner H., Hausberg M. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J. Hypertens. 2007, 25:639-647.
9. Caprio M., Newfell B.G., la Sala A., Baur W.E., Fabbri A., Rosano G., Mendelsohn M.E., Jaffe I.Z. Functional mineralocorticoid receptors in human vascular endothelial cells regulate ICAM-1 expression and promote leukocyte adhesion. Circ. Res. 2008, 102:1359-1367.
10. Takai S., Jin D., Muramatsu M., Kirimura K., Sakonjo H., Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46:1135-1139.
11. Gamliel-Lazarovich A., Gantman A., Coleman R., Jeng A.Y., Kaplan M., Keidar S. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J. Hypertens. 2010, 28:1900-1907.
12. Keidar S., Kaplan M., Pavlotzky E., Coleman R., Hayek T., Hamoud S., Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
13. Łabuzek K., Liber S., Bułdak Ł., Machnik G., Liber J., Okopień B. Eplerenone promotes alternative activation in human monocyte-derived macrophages. Pharmacol. Rep. 2013, 65:226-234.
14. Tostes R.C., Touyz R.M., He G., Chen X., Schiffrin E.L. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin. Sci. 2002, 103:25S-30S.
15. Rickard A.J., Morgan J., Tesch G., Funder J.W., Fuller P.J., Young M.J. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54:537-543.
16. Usher M.G., Duan S.Z., Ivaschenko C.Y., Frieler R.A., Berger S., Schütz G., Lumeng C.N., Mortensen R.M. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Investig. 2010, 120:3350-3364.
17. Bienvenu L.A., Morgan J., Rickard A.J., Tesch G.H., Cranston G.A., Fletcher E.K., Delbridge L.M., Young M.J. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 2012, 153:3416-3425.
18. Bergmann A., Eulenberg C., Wellner M., Rolle S., Luft F., Kettritz R. Aldosterone abrogates nuclear factor kappaB-mediated tumor necrosis factor alpha production in human neutrophils via the mineralocorticoid receptor. Hypertension 2010, 55:370-379.
19. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 2011, 11:519-531.
20. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
21. Schönbeck U., Mach F., Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 1998, 161:3340-3346.
22. Reichel C.A., Rehberg M., Bihari P., Moser C.M., Linder S., Khandoga A., Krombach F. Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling. J. Leukoc. Biol. 2008, 83:864-874.
23. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 2002, 37:375-536.
24. Vandooren J., Van den Steen P.E., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 2013, 48:222-272.
25. Kjeldsen L., Johnsen A.H., Sengelov H., Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993, 268:10425-10432.
26. Yan L., Borregaard N., Kjeldsen L., Moses M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001, 276:37258-37265.
27. Collins S.J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987, 70:1233-1244.
28. Owen C.A., Hu Z., Barrick B., Shapiro S.D. Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am. J. Respir. Cell Mol. Biol. 2003, 29:283-294.
29. 2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. J. Immunol. 2004, 172:7060-7068.
30. Callera G.E., Touyz R.M., Tostes R.C., Yogi A., He Y., Malkinson S., Schiffrin E.L. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via s-Src. Hypertension 2005, 45:773-779.
31. Lee Y.S., Kim J.A., Kim K.L., Jang H.S., Kim J.M., Lee J.Y., Shin I.S., Lee J.S., Suh W., Choi J.H., Jeon E.S., Byun J., Kim D.K. Aldosterone upregulates connective tissue growth factor gene expression via p38 MAPK pathway and mineralocorticoid receptor in ventricular myocytes. J. Korean Med. Sci. 2004, 19:805-811.
32. Fu G.X., Xu C.C., Zhong Y., Zhu D.L., Gao P.J. Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK. Endocrine 2012, 42:676-683.
33. Nagai Y., Miyata K., Sun G.P., Rahman M., Kimura S., Miyatake A., Kiyomoto H., Kohno M., Abe Y., Yoshizumi M., Nishiyama A. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005, 46:1039-1045.
34. Huang L.L., Nikolic-Paterson D.J., Ma F.Y., Tesch G.H. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signalling. Nephron Exp. Nephrol. 2012, 120:e115-e122.
35. Rude M.K., Duhaney T.A.S., Kuster G.M., Judge S., Heo J., Colucci W.S., Siwik D.A., Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 2005, 46:555-561.
36. Walczak C., Gaignier F., Gilet A., Zou F., Thornton S.N., Ropars A. Aldosterone increases VEGF-A production in human neutrophils through PI3K, ERK1/2 and p38 pathways. Biochim. Biophys. Acta 2011, 1813:2125-2132.
37. Grossmann C., Benesic A., Krug A.W., Freudinger R., Mildenberger S., Gassner B., Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 2005, 19:1697-1710.
38. McEneaney V., Harvey B.J., Thomas W. Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell line. J. Steroid Biochem. Mol. Biol. 2007, 107:180-190.
39. Huang S., Zhang A., Ding G., Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am. J. Physiol.: Ren. Physiol. 2009, 296:F1323-F1333.
40. Lewkowicz P., Tchórzewski H., Dytnerska K., Banasik M., Lewkowicz N. Epidermal growth factor enhances TNF-alpha-induced priming of human neutrophils. Immunol. Lett. 2005, 96:203-210.
41. Kim S., Choi J.H., Lim H.I., Lee S.K., Kim W.W., Cho S., Kim J.S., Kim J.H., Choe J.H., Nam S.J., Lee J.E., Yang J.H. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal. 2009, 21:892-898.
42. Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., Chorazyczewski J., Feldman R.D. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011, 57:442-451.
43. Gros R., Ding Q., Liu B., Chorazyczewski J., Feldman R.D. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am. J. Physiol.: Cell Physiol. 2013, 304:C532-C540.
44. Mitra S., Abraham E. Participation of superoxide in neutrophil activation and cytokine production. Biochim. Biophys. Acta 2006, 1762:732-741.
45. Coxon P.Y., Rane M.J., Uriarte S., Powell D.W., Singh S., Butt W., Chen Q., McLeish K.R. MAPK-activated protein kinase-2 participates in p38 MAPK-dependent and ERK-dependent functions in human neutrophils. Cell Signal. 2003, 15:993-1001.
46. Christoffersson G., Vågesjö E., Vandooren J., Lidén M., Massena S., Reinert R.B., Brissova M., Powers A.C., Opdenakker G., Phillipson M. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012, 120:4653-4662.
47. Raiden S., Giordano M., Andonegui G., Trevani A.S., López D.H., Nahmod V., Geffner J.R. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucyl-phenylalanine to neutrophil receptors. J. Pharmacol. Exp. Ther. 1997, 281:624-628.
48. Mazak I., Fiebeler A., Muller D.N., Park J.K., Shagdarsuren E., Lindschau C., Dechend R., Viedt C., Pilz B., Haller H., Luft F.C. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004, 109:2792-2800.
49. Montezano A.C., Callera G.E., Yogi A., He Y., Tostes R.C., He G., Schiffrin E.L., Touyz R.M. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1511-1518.
50. El Bekay R., Alvarez M., Monteseirin J., Alba G., Chacon P., Vega A., Martin-Nieto J., Jimenez J., Pintado E., Bedoya F.J., Sobrino F. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood 2003, 102:662-671.
51. Nabah Y.N., Mateo T., Estellés R., Mata M., Zagorski J., Sarau H., Cortijo J., Morcillo E.J., Jose P.J., Sanz M.J. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 2004, 110:3581-3586.
52. Guo R.W., Yang L.X., Wang H., Liu B., Wang L. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul. Pept. 2008, 147:37-44.
53. Cipollone F., Fazia M., Iezzi A., Pini B., Cuccurullo C., Zucchelli M., de Cesare D., Ucchino S., Spigonardo F., De Luca M., Muraro R., Bei R., Bucci M., Cuccurullo F., Mezzetti A. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004, 109:1482-1488.